A crane collapses kills 2 at a Florida construction site, officials say
The collapse occurred at the site of the new Cape Canaveral Hospital in Merritt Island, which is on the Atlantic coast about 60 miles (90 kilometers) east of Orlando.
Two people were transported to a nearby hospital, where they later died, Brevard County Sheriff's Office spokesperson Tod Goodyear said. Officials didn't immediately identify the victims.
The area had been hit by rain and strong winds Wednesday afternoon, but the exact cause of the collapse was under investigation.
The Cape Canaveral Hospital began construction last year and is expected to open to the public in 2027. It will replace the existing Cape Canaveral Hospital in nearby Cocoa Beach.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health
The Investment is part of BrainsWay's ongoing strategy to acquire minority positions in leading U.S. mental health providers to help them raise awareness for and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, Aug. 20, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ('BrainsWay' or the 'Company'), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it has entered into a strategic equity financing agreement with Axis Management Company, Inc. ('Axis Integrated Mental Health' or 'Axis'), a management services organization servicing several mental health clinics in Colorado. Under the terms of the agreement, BrainsWay will invest $2.3 million initially, and an additional potential $1 million milestone-based investment, for a minority position in Axis in the form of a preferred, annually compounding security. The agreement also provides for a redemption mechanism relating to the shares. 'Our minority-stake investment in Axis follows our previous investment in Stella, and is part of BrainsWay's broader initiative to accelerate access to and awareness of innovative mental health treatments, including Deep TMS Therapy, while continuing to maintain our core focus on advancing our scientific and technological capabilities to ensure best-in-class support for all our customers. Within this strategy, our investments provide capital injections into high performing healthcare providers, which then allows these businesses to invest in growth drivers and launch new locations,' said Hadar Levy, Chief Executive Officer of BrainsWay. 'We see tremendous opportunities for these healthcare providers to offer expanded services and grow their businesses once they secure the necessary capital.' 'Axis offers a robust clinical services platform and is committed to achieving rapid growth and excellent patient outcomes. We are thrilled to support and collaborate with them as their business continues to scale from a well-respected regional platform to one with a larger footprint, enhancing their delivery of life-changing care to additional patients,' concluded Mr. Levy. 'Our partnership with BrainsWay was born out of a mutual desire to deliver the best cutting-edge mental health treatments to the communities we serve,' stated Chris Perez, Chief Executive Officer of Axis. 'Given the peerless reputation of BrainsWay and its proprietary Deep TMS technology, we realize the value this strategic partnership will provide as we further advance in our mission of putting patients first through our best-in-class support.' About BrainsWay BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit About Axis Axis Integrated Mental Health services its leading mental health practices, which are dedicated to transforming lives through a truly comprehensive, integrative model of care. With a team of board-certified specialists combining modern psychiatry and psychotherapy with advanced treatments including Deep TMS™ and Spravato®, Axis utilizes an evidence-based, holistic therapeutic approach to treat patients, all through a single, coordinated care experience under one roof. For more information, please visit Forward-Looking Statement This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential' or similar words, and also includes any financial guidance and projections contained herein. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the failure of our investments in management services organizations and/or other clinic-related entities to produce profitable returns; inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company's anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company's intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading 'Risk Factors' in the Company's filings with the U.S. Securities and Exchange Commission. Contacts: BrainsWay:Ido MaromChief Financial Investors:Brian RitchieLifeSci Advisors LLCbritchie@ in to access your portfolio
Yahoo
32 minutes ago
- Yahoo
First PRIZM Study Participant Enrolled in Tisento Therapeutics' Open-Label Extension Study in MELAS
Participants Who Complete Treatment in Global Phase 2b PRIZM MELAS Study Are Eligible to Enroll CAMBRIDGE, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Tisento Therapeutics today announced that the first participant has enrolled in the company's open-label extension study in MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes). The extension study (NCT06961344) is evaluating the long-term safety and tolerability of zagociguat in individuals with MELAS who complete treatment in the global Phase 2b PRIZM study, which is expected to complete screening in the next months. The extension study is intended to provide uninterrupted access to zagociguat for clinical trial participants for up to two years and evaluate the long-term safety of zagociguat. 'We're pleased to reach the important milestone of enrolling the first PRIZM study participant into our open-label extension study,' said Peter Hecht, Ph.D., chief executive officer of Tisento. 'Enthusiastic engagement by MELAS patients and physicians is powering momentum in our development program, and we look forward to completing PRIZM enrollment in the next few months.' The PRIZM study is actively enrolling in the U.S., Canada, Australia, United Kingdom, Italy, and Germany, and interested individuals are encouraged to discuss participation with their physician. PRIZM is evaluating the impact of zagociguat treatment on fatigue, cognitive performance, and other key aspects of MELAS. The clinical outcome assessments and endpoint strategy for the PRIZM study were informed by Tisento's interview study in which individuals living with MELAS described the symptoms and impacts of the disease that are most important to them. Participants who complete treatment in PRIZM have the opportunity to enroll in the open-label extension study. About the PRIZM Study PRIZM – a Phase 2b Randomized, Placebo-Controlled Trial Investigating Zagociguat in MELAS – is evaluating the efficacy and safety of oral zagociguat 15 mg or 30 mg compared to placebo when administered once-daily for 12 weeks in participants with genetically and phenotypically defined MELAS. The PRIZM study has a crossover design, with two 12-week treatment periods separated by a 4-week washout period. All participants will receive zagociguat during one of the 12-week periods and placebo during the other. Participants who complete treatment in the study have the opportunity to enroll in an open-label extension study. The global PRIZM study is now enrolling approximately 44 participants at mitochondrial disease centers of excellence in the U.S., Italy, Germany, United Kingdom, Australia, and Canada. For more information, please visit or (NCT06402123). Interested individuals can also reach out to their physicians for participation details. About Zagociguat Zagociguat is a once-daily, oral, clinical-stage investigational medicine with potential to positively impact both peripheral and central nervous system manifestations of mitochondrial diseases. Zagociguat stimulates soluble guanylate cyclase (sGC), an enzyme that is found in virtually every cell in every tissue of the body and is part of a system of cellular mechanisms that control critical physiological functions including neuronal function and blood flow. A first-in-class, brain-penetrant sGC stimulator, zagociguat is hypothesized to rebalance dysregulated cellular pathways in MELAS. By restoring cellular functions that support mitochondria, zagociguat may help restore mitochondrial energy production and physiological function. In a Phase 2a study in patients with MELAS, zagociguat exhibited a favorable safety profile, exposure throughout the body including in the central nervous system, and improvements in neuronal function, mitochondrial function, and blood flow in the brain. Zagociguat is currently being evaluated as a treatment for MELAS in the Phase 2b PRIZM study. Zagociguat received Fast Track designation from the U.S. Food and Drug Administration for the treatment of MELAS. Fast Track is a process designed to facilitate the development and potentially expedite the review of medicines to treat serious conditions and fill an unmet medical need, with the goal of getting important new drugs to patients earlier. For more information, visit About Tisento Therapeutics Tisento Therapeutics, a privately held biotech company, is developing novel medicines to treat diseases with significant unmet need, beginning with MELAS and other genetic mitochondrial diseases. Ti sento means 'I hear you' in Italian; our approach to innovation begins with listening to patients and then channeling what we learn into decisive actions that shape our research and clinical programs. Tisento is guided by a high-caliber internal team of biopharma veterans and an extensive external network of expert physicians, patient advocacy groups, researchers, industry-leading vendors, and other close collaborators who are partners in our mission to develop meaningful treatments for mitochondrial diseases. Learn more at our website, or connect with us on LinkedIn, Facebook, X (@tisentotx), or Bluesky. Contact Tisento Media RelationsJessi Rennekamp, Astrior CommunicationsEmail: jessi@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
32 minutes ago
- Yahoo
This Advice From Economics Might Be The Answer To Your Parenting Burnout. Here's Why.
When my wife and I brought our first child home from the hospital, we planned on diligently following all of the expert recommendations regarding his care: He would breastfeed exclusively and sleep in a bassinet beside our bed, on his back, in a properly ventilated room. We had read about SIDS and would take every possible precaution. What could be more important that preventing harm from coming to our child? Almost immediately, however, we ran into trouble. Our baby stopped peeing. He was dehydrated and hungry, somehow, although he spent pretty much all day at my breast. So we feed him some infant formula using a medicine dropper, which he lapped up hungrily, sending me into a shame spiral that took months of therapy to crawl out of. But at least with the supplementary formula we were able to keep him happily fed. Related: The second problem sent us into a territory that was even more mortifying. In spite of the fact that my breasts were only partially functional, the baby was extremely attached to them. As in, he would only sleep if they were right there, right beside him, skin to skin with his tiny cheek. Every time he feel asleep while nursing and unlatched his little rosebud lips, I moved as stealthily as possible to try to get him into the bassinet. But more often than not, he woke and started crying. And even if I could get him to lie in the bassinet, it often didn't last long. The end result was that I spent a lot of time nursing him in the chair, and, in my desperation and exhaustion, I often fell asleep. My wife could tell, just by looking at us, that this was not a safe situation. Since it wasn't possible to get him into the bassinet, we just cleared our bed of blankets and pillows and let him sleep where he wanted to, right next to my body. We didn't tell anyone. We had been taught that bed-sharing with a baby was deadly, so we certainly weren't going to admit to doing it. This was all back in 2009, before economist Emily Oster began publishing her bestselling books, in which she brings a unique, data-driven perspective to the art of parenting. In her second book, 'Cribsheet,' she explains how holding up the ideal infant sleeping arrangement as the only permissible option can actually lead parents to put their babies in more danger. Because although it is safest to have baby sleep on a separate surface, it is much more dangerous to sleep with a baby on a sofa or armchair. Sixty-seven times more dangerous. Though it wasn't a best-case scenario that the baby wasn't in the bassinet, he was a lot safer sleeping next to me on the mattress instead of in the recliner. Infant sleep, Oster writes, is one example of a scenario in which we might benefit from considering what she calls 'second best' parenting. It is a term she borrows from economics. 'When we are giving advice in parenting, we tend to be absolutist: There is the best option and then everything else,' Oster told HuffPost, She has used the term 'outer darkness' to refer to everything else — as in, if it's not the best option, it's all equally bad and scary. But this all-or-nothing approach doesn't apply well to infant sleep, where we clearly have a first best option (bassinet/crib in same room as parent) followed by a second best option (on a clear, flat sleeping surface next to the nursing parent) and then, way, way down, the 67th best option of a desperate mother accidentally falling asleep in an armchair while holding the baby because she has been told that under no circumstances should she consider bringing the baby into her bed. 'The idea of 'second best' is to recognize that within the category of 'other options,' some are better than others. The second best is the best option that we can achieve,' Oster said. She thinks that this can be a useful framework for other parenting choices, too, such as what to feed our children. 'We're told the best snack for our kids is, say, a whole apple and a glass of water. But what if your kid doesn't eat that? We don't help people pick well among the options their child will eat. You'd be forgiven for thinking that once you're going to applesauce, you might as well give a pile of cookies. But actually those aren't the same.' Believing that there is only one right way and the rest are wrong sets us up to see only black and white when actually there are so many shades of gray. 'When we tell people that it's the 'best or the rest,' we do not allow for them to choose smartly among the rest,' Oster said. In addition to not choosing well, this thinking makes people feel badly about how they're parenting. 'When we tell people they aren't doing their best, that disempowers them. And no one parents well from a place of shame,' Oster added. Finding Other Good Options Beyond Perfect The advantage of referring to 'second best' is that, with the word 'best,' parents are left with space to take pride in their parenting. A silver or bronze medal is still a win, after all. The argument that Oster is making is similar to that of 'good enough parenting,' an idea popularized in the 1950s by Donald Winnicott. Parenting coach Kristene Geering told HuffPost that this is the framework she uses with parents. 'It's based on the notion that there is no such thing as perfect,' Geering explained. 'Part of being human is that there are challenges, there are times when there's no clear or easy path (which is also how we learn). There is no 'best.' You take what information you have, make a decision based on that and then you learn as you go along.' Geering thinks this dovetails nicely with Carol Dweck's 'growth mindset,' in which as we learn more, we do better. Geering said she often tells families that 'we're all doing the best we can with what we have' and advises, 'Learn from your mistakes, repair as you go, and show your children how to hold compassion for yourself and those around you.' She likes the 'good enough' phrasing because it makes room for the idea that there are many different options that might be 'bests' for different families dealing with different circumstances. Geering agrees with Oster that it's important to move parents out the space of 'all is lost,' where they may get trapped in their shame. She said that where she works in Silicon Valley, 'I see a lot of parents fall into this trap of trying to be 'perfect' ... and then researching themselves into a state where they're almost frozen with indecision.' With an endless amount of information readily available, this isn't an uncommon place for parents to land. 'I've fallen into this trap as well,' Geering admitted. 'Things like which school to attend, which activity to sign up for... it's really overwhelming.' Make Peace With Your 'Good Enough' Using a 'second best' or 'good enough' mindset doesn't come naturally to people raised in a culture of competition. But sooner or later, all parents are faced with a scenario that challenges expectations of perfection. For Geering, a clear example of this in her own family was pandemic schooling. 'I watched my own kids struggle on 'Zoom school,' to the point where it was clear this would never work for them. So I pulled them, and we did homeschool for a year... while my husband and I both worked full time. Was it perfect? Nope. Was it 'second best'? I have no idea.' Her kids are 'still catching up on math,' she said, although they also 'gained a lot of skills in independence.' 'Instead of beating myself up on all the math they missed out on, I looked at it from the point of view that I was doing the best I could in really awful circumstances. And I looked at all the moms in my friend groups and the parents I was working with, and I saw everyone making different decisions, based on their specific circumstances. Absolutely no one did the 'best' thing... because there was no 'best' thing.' Whether you think of it as 'second best' or 'good enough,' parenting within this framework, as opposed to one in which there is only one right option for all families, makes room for you to give yourself some grace. An added benefit of letting go of a perfection-or-nothing mindset is the weight that this takes off of our kids. If we 'show them how to repair the relationship when we mess up and share our learning process with them,' Geering said, 'it lets them be compassionate with themselves, learn from their mistakes, create authentic and meaningful relationships with others, and have a growth mindset as their default throughout life. That's pretty powerful stuff.' Related... Parents Are Lying About Where Their Babies Sleep At Night. Here's Why That's A Problem. What Second-Time Parents Wish They Didn't Stress About The First Time Around This 1 Thing May Be Wearing Parents Out Everywhere
